New drugs to prevent and treat hyperkalemia

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 6, 2016, Pages 524-528

  Lepage, Laurence ^a   Desforges, Katherine ^a   Lafrance, Jean Philippe ^a,b,c  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

hyperkalemia; patiromer; sodium polystyrene sulfonate; ZS 9 compound

Indexed keywords

PATIROMER; POLYSTYRENESULFONATE SODIUM; SODIUM ZIRCONIUM CYCLOSILICATE; CATION EXCHANGE RESIN; POLYMER; POLYSTYRENE DERIVATIVE; POLYSTYRENESULFONIC ACID; POTASSIUM; SILICATE; ZS-9 COMPOUND;

CHRONIC KIDNEY DISEASE; CONSTIPATION; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDEMA; GASTROINTESTINAL SYMPTOM; HOSPITAL PATIENT; HUMAN; HYPERKALEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; BLOOD; CHRONIC KIDNEY FAILURE;

CATION EXCHANGE RESINS; HUMANS; HYPERKALEMIA; POLYMERS; POLYSTYRENES; POTASSIUM; RENAL INSUFFICIENCY, CHRONIC; SILICATES;

EID: 84984674596     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000272     Document Type: Review

References (42)

1. Fleet JL, Shariff SZ, Gandhi S, et al. Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission. BMJ Open 2012; 2:. doi: 10.1136/bmjopen-2012-002011.
2. Drawz PE, Babineau DC, Rahman M. Metabolic complications in elderly adults with chronic kidney disease. J Am Geriatr Soc 2012; 60:310-315.
3. Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol 2012; 7:1234.
4. Drion I, Joosten H, Dikkeschei LD, et al. eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population. Eur J Intern Med 2009; 20:722-727.
5. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009; 169:1156- 1162.
6. Hayes J, Kalantar-Zadeh K, Lu JL, et al. Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: The role of race. Nephron Clin Pract 2012; 120:c8-c16.
7. Korgaonkar S, Tilea A, Gillespie BW, et al. Serum potassium and outcomes in CKD: Insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol 2010; 5:762-769.
8. Susantitaphong P, Sewaralthahab K, Balk EM, et al. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: Ameta-analysis. Am J Hypertens 2013; 26:424-441.
9. Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol 2014; 10:653-662.
10. Evans KJ, Greenberg A. Hyperkalemia: A review. J Intensive Care Med 2005; 20:272-290.
11. Sousa AG, Cabral JV, El-Feghaly WB, et al. Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management. World J Diabetes 2016; 7:101-111.
12. American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care 2015; 38 (Suppl 1):S49-S57.
13. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3:1-150.
14. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240-e327.
15. Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther 2012; 30:e156-e166.
16. Sterns RH, Grieff M, Bernstein PL. Treatment of hyperkalemia: Something old, something new. Kidney Int 2016; 89:546-554.
17. DeFronzo RA. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 1980; 17:118-134.
18. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin- aldosterone system. N Engl J Med 2004; 351:585-592.
19. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (5 Suppl 1):S1-S290.
20. Elliott MJ, Ronksley PE, Clase CM, et al. Management of patients with acute hyperkalemia. CMAJ 2010; 182:1631-1635.
21. Iqbal Z, Friedman EA. Preferred therapy of hyperkalemia in renal insufficiency: Survey of nephrology training-program directors. N Engl J Med 1989; 320:60-61.
22. Scherr L, Ogden DA, Mead AW, et al. Management of hyperkalemia with a cation-exchange resin. N Engl J Med 1961; 264:115-119.
23. Evans BM, Jones NC, Milne MD, Yellowlees H. Ion-exchange resins in the treatment of anuria. Lancet (London, England) 1953; 265:791- 795.
24. Administration UFaD. Kayexalate (sodium polystyrene sulfonate) powder. 2011; Available from: Http://www.fda.gov/Safety/MedWatch/SafetyInformation/ ucm186845.htm. [Accessed 16 May 2016]
25. Harel Z, Harel S, Shah PS, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: A systematic review. Am J Med 2013; 126:264.e9-264.e24.
26. Watson MA, Baker TP, Nguyen A, et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: A retrospective cohort study. Am J Kidney Dis 2012; 60:409-416.
27. Chernin G, Gal-Oz A, Ben-Assa E, et al. Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy. Clin Cardiol 2012; 35:32-36.
28. Lepage L, Dufour AC, Doiron J, et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol 2015; 10:2136-2142.
29. Administration UFaD. FDA Drug Safety Communication: FDA requires drug interaction studies with potassium-lowering drug Kayexalate (sodium polystyrene sulfonate). 2015; Available from: Http://www.fda.gov/Drugs/DrugSafety/ ucm468035.htm. [Accessed 16 May 2016]
30. Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011; 32:820-828.
31. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015; 372:211-221.
32. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: The AMETHYSTDN randomized clinical trial. JAMA 2015; 314:151-161.
33. Bushinsky DA, Williams GH, Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int 2015; 88:1427-1433.
34. Stavros F, Yang A, Leon A, et al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One 2014; 9:e114686.
35. Ash SR, Singh B, Lavin PT, et al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int 2015; 88:404-411.
36. Packham DK, Kosiborod M. Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia. Expert Opin Drug Metab Toxicol 2016; 12:567-573.
37. Rafique Z, Peacock WF, LoVecchio F, Levy PD. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia. Expert Opin Pharmacother 2015; 16:1727-1734.
38. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015; 372:222.
39. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: The HARMONIZE randomized clinical trial. JAMA 2014; 312:2223-2233.
40. Kosiborod M, Peacock WF, Packham DK. Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia. N Engl J Med 2015; 372:1577- 1578.
41. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:543-551.
42. Georgianos PI, Sarafidis PA. New potassium binders: A call to test their efficacy and safety in dialysis patients. Am J Kidney Dis 2016; 67:165-166.